HNC042

HNC042 is an investigational small molecule drug developed as a neuraminidase inhibitor for the prevention and treatment of influenza virus infection. It is designed to inhibit both wild-type and oseltamivir-resistant (H274Y mutant) strains of influenza neuraminidase, showing high inhibitory activity in preclinical studies. The drug has been evaluated in multiple Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics following intravenous administration in healthy volunteers. The primary developer is Guangzhou Henovcom Bioscience (also referred to as Guangzhou Koncen Bioscience), with ZBD Pharmaceutical holding exclusive rights for development, registration, production, and commercialization within China[2][4][6].